Skip to main content
. 2019 Jul 30;13:755. doi: 10.3389/fnins.2019.00755

FIGURE 8.

FIGURE 8

Activation of PZ Phox2B-expressing neurons during the active period (19:00 or ZT12). (A) Hourly amount of wakefulness (A1), SWS (A2) and REM sleep (A3) following CNO (0.3 mg/kg, N = 4 mice) as compared with control injection. (B1–B3) Number of episodes (±S.E.M.) of wakefulness (W), SWS or REM sleep (RS) in each bout length and (B1’–B3’) time-weighted frequency histograms showing the proportion (±S.E.M.) of W, SWS or RS amounts in each bout length as a percentage of the total amount of W, SWS or RS during the 3 h post-injection period (19:00–22:00; N = 4). (C1–C3) Sleep-wake power spectrum changes over baseline during the 3 h (19:00–22:00) post CNO (0.3 mg/kg, N = 3 mice) injection as compared with control injection; and the quantitative changes (±S.E.M.) in power for the δ (0.4–5 Hz), θ (5–9 Hz), α (9–15 Hz), β (15–30 Hz), low γ (30–60 Hz) and high γ (60–120 Hz) frequency bands (±S.E.M.) following vehicle or CNO (0.3 mg/kg, N = 3 mice) administrations. Power spectral analysis was not performed for REM sleep due to the low amount of this vigilance stage. Control injection in Black, CNO injection in orange; no significant change, two-way ANOVA followed by a post hoc Bonferroni test.